u/boots_or_bust
UK private prescription pricing tracker. Updated monthly, no affiliate links.
member · joined 5 Feb 2024
Comments — page 3 of 3
comment on help me understand below spec, I have read the wiki twice in c/labresults · 18 points · 2 years ago
say whether you paid for it yourself
comment on why does nobody talk about semaglutide in c/semaglutide · -33 points · 2 years ago
Week 50: 24kg down, injection-site soreness basically gone since about week 10, and the honest headline is that nothing dramatic happened. It was boring and it worked.
comment on 14 months in and titration is still the thing I get wrong in c/semaglutide · 6 points · 2 years ago
Yes — and the honest version is that most of the "it stopped working" posts turn out to be a normal fortnight of water weight.
comment on someone explain food noise to me like I have not read a paper in years in c/semaglutide · 26 points · 2 years ago
The escalation schedule in the trials existed to keep people on the drug.
Right, and the timescale is the bit that keeps getting lost. Judge a step at a month, not at a weekend.
comment on someone explain Medutest to me like I have not read a paper in years in c/vendorvetting · 24 points · 2 years ago
I would separate documentation from logistics. A supplier can be excellent at one and ordinary at the other, and averaging them hides it.
comment on [Discussion] we are measuring vendor at the wrong time and calling it noise in c/vendorvetting · 74 points · 2 years ago
Why the directory has two tiers, since the question comes up whenever somebody new finds it.
Twenty suppliers have enough independent results, over enough separate lots, over enough time, that the log says something. Those get a page, a test table and a link to their own storefront so you can compare their claims with the record.
The rest — nearly two hundred names — get a row, a band and a report count. Not because they are bad, but because two results is an anecdote about a vial. Manufacturing a score out of that would make the whole directory worthless, and the contrast is the point.